Bill > SB415

This bill prohibits manufacturers or wholesale distributors from engaging in price gouging in the sale of essential generic drugs. It requires the Maryland Medical Assistance Program to notify the manufacturer and the Attorney General of significant price increases for essential generic drugs with limited competition. The manufacturer must then submit a statement to the Attorney General detailing the cost components, any increased costs, and efforts to expand access to the drug. The Attorney General can compel the manufacturer to provide records and documents, and can petition a court to order the manufacturer to make the drug available to state health plans and programs at the prior price for up to a year, impose civil penalties, and restore money to consumers if a price increase is found to violate the law.